US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Provident

16.57

+0.03500.21%

Volume:99.72K

Turnover:1.65M

Market Cap:2.16B

PE:13.94

High:16.61

Open:16.55

Low:16.40

Close:16.53

Loading ...

Overview Company News Filings

Provident Financial Services, Inc. Announces First Quarter Earnings and Declares Quarterly Cash Dividend

Press Release: DEFENSE METALS ANNOUNCES BEST EFFORTS PRIVATE PLACEMENT FINANCING FOR GROSS PROCEEDS OF UP TO $8 MILLION AND CONCURRENT NON-BROKERED FINANCING FOR GROSS PROCEEDS OF UP TO $1,000,000

Press Release: Hot Chili Quarterly Report

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

Why Summit Therapeutics Inc. (SMMT) Went Up On Wednesday

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

3 Top Dividend Stocks Offering Up To 6.1% Yield

Simply Wall St.

Solaris completes Warintza drilling campaign and advances key de-risking milestones ahead of major near-term value catalysts

Health Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

Why DroneShield, Kingsgate, Santana, and Star shares are pushing higher today

Santana Minerals Refines Gold Project Strategy to Enhance Viability

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer

Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Here's Why Summit Therapeutics Stock Soared 15% on Friday

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PFS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident","latestPrice":16.565,"timestamp":1745941878058,"preClose":16.53,"halted":0,"volume":99717,"delay":0,"floatShares":126167377,"shares":130663184,"eps":1.188092,"marketStatus":"Trading","change":0.035,"latestTime":"04-29 11:52:11 EDT","open":16.55,"high":16.61,"low":16.395,"amount":1648686.076767,"amplitude":0.013007,"askPrice":16.56,"askSize":52,"bidPrice":16.54,"bidSize":2,"shortable":3,"etf":0,"ttmEps":1.188092,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1745956800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":16.53,"dividendRate":0.057954,"preHourTrading":{"tag":"盘前","latestPrice":16.53,"preClose":16.53,"latestTime":"08:02 EDT","volume":2,"amount":33,"timestamp":1745928175006},"postHourTrading":{"tag":"盘后","latestPrice":16.53,"preClose":16.53,"latestTime":"18:30 EDT","volume":36464,"amount":602750.39,"timestamp":1745879424982},"volumeRatio":0.325294,"impliedVol":0.0617,"impliedVolPercentile":0.088},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","floatShares":126167377,"roa":"0.77%","roe":"6.77%","lyrEps":1.053397,"volumeRatio":0.325294,"shares":130663184,"dividePrice":0.96,"high":16.61,"amplitude":0.013007,"preClose":16.53,"low":16.395,"week52Low":13.07,"pbRate":"0.81","psRate":"3.09","week52High":22.24,"institutionHeld":0.6698,"latestPrice":16.565,"committee":-0.925926,"eps":1.188092,"divideRate":0.057954,"volume":99717,"delay":0,"ttmEps":1.188092,"open":16.55,"prevYearClose":18.87,"prevWeekClose":16.54,"prevMonthClose":17.17,"prevQuarterClose":17.17,"fiveDayClose":16.01,"twentyDayClose":17.17,"sixtyDayClose":18.57},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530699907","title":"Provident Financial Services, Inc. Announces First Quarter Earnings and Declares Quarterly Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2530699907","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530699907?lang=en_us&edition=fundamental","pubTime":"2025-04-25 05:00","pubTimestamp":1745528400,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., April 24, 2025  -- Provident Financial Services, Inc.   reported net income of $64.0 million, or $0.49 per basic and diluted share for the three months ended March 31, 2025, compared to $48.5 million, or $0.37 per basic and diluted share, for the three months ended December 31, 2024 and $32.1 million, or $0.43 per basic and diluted share, for the three months ended March 31, 2024. Net income for the three months ended March 31, 2025 was negatively impacted by a $2.7 million write-down on a foreclosed property, partially offset by a $624,000 profit on fixed asset sales related to the consolidation of three branches. While there were no transaction costs related to our merger with Lakeland Bancorp, Inc.  for the 2025 period, these costs totaled $20.2 million for the three months ended December31, 2024 and $2.2 million for the three months ended March 31, 2024, respectively.The net interest margin increased six basis points to 3.34% for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/provident-financial-services-inc-announces-210000833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS"],"gpt_icon":0},{"id":"2530385960","title":"Press Release: DEFENSE METALS ANNOUNCES BEST EFFORTS PRIVATE PLACEMENT FINANCING FOR GROSS PROCEEDS OF UP TO $8 MILLION AND CONCURRENT NON-BROKERED FINANCING FOR GROSS PROCEEDS OF UP TO $1,000,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2530385960","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530385960?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:01","pubTimestamp":1745524860,"startTime":"0","endTime":"0","summary":"DEFENSE METALS ANNOUNCES BEST EFFORTS PRIVATE PLACEMENT FINANCING FOR GROSS PROCEEDS OF UP TO $8 MILLION AND CONCURRENT NON-BROKERED FINANCING FOR GROSS PROCEEDS OF UP TO $1,000,000. /THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES/. The Agents will be paid by the Company on closing of the Offering a cash commission equal to 7% of the gross proceeds of the Offering, including on any exercise of the Agents' Option, other than in respect of sales of up to $1,000,000 to certain investors designated by the Company on a president's list  for which the Company shall pay a commission equal to 3.5%.The Agents will also receive on the Closing Date compensation options entitling the Agents to acquire that number of Common Shares (the \"Compensation S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4502","REE","BK4008","PFS","BEST","BK4195","BK4131","BK4124","FOR","BK4211","BK4558","UP","BK4024"],"gpt_icon":0},{"id":"2529581889","title":"Press Release: Hot Chili Quarterly Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2529581889","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529581889?lang=en_us&edition=fundamental","pubTime":"2025-04-24 23:03","pubTimestamp":1745506980,"startTime":"0","endTime":"0","summary":"Hot Chili Announces Preliminary Feasibility Study  & Maiden Ore Reserve  for the Costa Fuego Cu-Au Project. -- Low-risk, Chilean coastal copper development with advanced permitting -. multi-decade mine life, top quartile copper production scale3 and lowest. -- Strong economics and leverage to rising copper price:. -- Post-tax Net Present Value  of US$1.2 billion. (approximately, within a range of US$786 million to US$1.62. billion) and post-tax Internal Rate of Return  of 19%. -- Maiden ore reserve for Costa Fuego Copper-Gold Project . -- Probable Ore Reserves of 502 Mt at 0.37% Cu, 0.10 g/t Au, 0.49 g/t. Ag and 97 ppm Mo:  Across sulphide concentrator, oxide leach and. Hot Chili Announces PFS for Huasco Water & MOU for Seawater Supply to Costa Fuego. -- Strong economics for a large, multi-user, water business opportunity. -- Stage 1 PFS4  for 500L/s of potential seawater supply to Costa Fuego. -- Post-tax NPV8% of US$122 million and IRR of 19%. oxide and sulphide discovery, located 30","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1861217088.USD","LU1668664300.SGD","PFS","EIA","LU1861220207.SGD","BK4588","BK4211","DFS","BK7110","HCH.AU","LU2360107671.USD","LU0106831901.USD","IRR","BK4195","LU1791807156.HKD","BK4166"],"gpt_icon":0},{"id":"2529260691","title":"HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529260691","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529260691?lang=en_us&edition=fundamental","pubTime":"2025-04-24 08:00","pubTimestamp":1745452800,"startTime":"0","endTime":"0","summary":"HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025  -- HUTCHMED  Limited   today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American Association of Cancer Research  Annual Meeting 2025, taking place on April 25-30, 2025 in Chicago, Illinois.Targeting KEAP1/NRF2 signaling sensitizes KRAS-driven NSCLC to KRAS inhibitors. SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed  and/or -amplified  NSCLC post-osimertinib  treated with savolitinib  + osi. A phase I open-label positron-emission tomography study to determine brain exposure of [11C]savolitinib in healthy volunteers. A multi-cohort study of treatment regimens for metastatic colorectal cancer : Subgroup analysis of sequential therapy between fruquintinib and regorafenib. Wangxia Lv, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hutchmed-highlights-data-presented-aacr-000000843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0162691827.USD","LU0648001328.SGD","LU1366192091.USD","IE00BSNM7G36.USD","LU0170899867.USD","LU2417539215.USD","LU1668664300.SGD","LU2462157665.USD","LU2125154778.USD","BK4504","BK4006","BK4195","LU2125154935.USD","BK4211","LU0128525689.USD","BK4099","LU0052756011.USD","BK4588","BK4207","BK4007","LU0980610538.SGD","LU1267930227.SGD","BK4566","LU0310800965.SGD","BK4559","BK4516","F","LU0477156953.USD","LU0098860793.USD","BK4531","LU1201861249.SGD","BK4534","ORR","LU0106831901.USD","MT","LU0320765646.SGD","PFS","BK4585","LU1162221912.USD","LU0130102774.USD","LU1791807156.HKD","BK4574","LU2236285917.USD","LU2360032135.SGD","HCM","LU2456880835.USD","LU0072461881.USD","BK4561","BK4555","LU0130517989.USD"],"gpt_icon":0},{"id":"2529266260","title":"Why Summit Therapeutics Inc. (SMMT) Went Up On Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2529266260","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529266260?lang=en_us&edition=fundamental","pubTime":"2025-04-24 06:13","pubTimestamp":1745446436,"startTime":"0","endTime":"0","summary":"Wall Street’s major indices rebounded anew on Wednesday as worries about tariff policies and the Federal Reserve’s independence tapered off after President Donald Trump assured that he had no intentions of ousting Jerome Powell.The Nasdaq surged by 2.5 percent, the S&P 500 rose by 1.67 percent, while the Dow Jones increased by 1.07 percent.Ten companies mirrored the broader market optimism as optimistic investors resumed pouring funds into their stocks. In this article, we have identified Wednesday’s 10 best-performing stocks during the intra-day trading and detailed the reasons behind their strong performance.To come up with the list, we considered only the stocks with more than $2 billion in market capitalization and $5 million in intraday trading volume.Summit Therapeutics surged by 23.76 percent at intra-day trading on Wednesday, a fourth straight day, before ending the day just up by 21.5 percent at $33.23 apiece as investor sentiment was boosted by the positive results of its pha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-summit-therapeutics-inc-smmt-221356671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SMMT","BK4195","LU2488822045.USD","PFS","BK4211"],"gpt_icon":0},{"id":"2529668143","title":"Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2529668143","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529668143?lang=en_us&edition=fundamental","pubTime":"2025-04-24 04:15","pubTimestamp":1745439300,"startTime":"0","endTime":"0","summary":"Statistically significant and clinically meaningful progression-free survival  and overall survival  data for Zepzelca  and atezolizumab  combination underscore potential of first-line maintenance therapy for extensive-stage small cell lung cancer, a much-needed advancement for patients. Long-term outcomes and survival data for Ziiherahighlight its potential to reshape the treatment paradigm for newly diagnosed HER2+ gastroesophageal cancer patients. Efficacy and safety of dordaviprone  in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients. Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data. An oral abstract of the Phase 3 IMforte trial, which showed statistically significant and clinically meaningful survival benefit (progression-free survival (PFS) and overall survival (OS) for the combination of Zepzelca and atezolizumab (Tecentriq) for extensive-stage small cell lung cancer (ES-SCLC) patients receiving treatmen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-showcases-transformative-data-201500637.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jazz-pharmaceuticals-showcases-transformative-data-201500637.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4197","BTC","JAZZ","BK4097","BK4162","PFS","LU0109394709.USD","LU0320765992.SGD","IE00BN0W2V16.EUR","CDC","IHC","OS","IE00BN0W2T93.GBP","ORR","BK4211","CPK","BK4533","IE00BN0W2W23.USD","LU0823416689.USD","BK4007","LU0889565916.HKD","BK4195","BK4532"],"gpt_icon":0},{"id":"2529617659","title":"Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2529617659","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529617659?lang=en_us&edition=fundamental","pubTime":"2025-04-24 00:37","pubTimestamp":1745426220,"startTime":"0","endTime":"0","summary":"This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol Myers Squibb BMY was down on data from the schizophrenia study while Regeneron REGN was in the spotlight on updates on key drugs.Bristol Myers announced disappointing top-line results from the phase III ARISE study on schizophrenia drug Cobenfy . The study is evaluating the efficacy and safety of Cobenfy as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia.Treatment with Cobenfy as an adjunctive demonstrated a 2.0-point reduction in the Positive and Negative Syndrome Scale total score compared to placebo with an atypical antipsychotic at week six. However, this data did not reach the threshold for statistical significance for the primary endpoint. Shares of BMY were down following the data announcement.Preliminary analyses suggest that Cobenfy as an adjunctive treatment to an atypical antipsychotic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-bmy-down-163700964.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989771016.USD","LU2089984988.USD","LU0225284248.USD","LU1670711123.USD","IE00B19Z3B42.SGD","BK4532","LU1670710588.SGD","REGN","IE00B7SZLL34.SGD","BK4583","LU1839511570.USD","IE00B3T34201.USD","GILD","LU0058720904.USD","OS","LU1093756168.USD","BK4007","LU0225771236.USD","LU2133065610.SGD","CRL","BK4559","LU2023250504.SGD","SNY","LU1868837300.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE0002141913.USD","LU0234570918.USD","BMY","LU0306807586.USD","LU0868494617.USD","LU2362541273.HKD","IE00BKVL7J92.USD","PFS","BK4585","LU2362541513.USD","LU0306806265.USD","LU0889565916.HKD","LU2237438978.USD","LU1291159041.SGD","LU1670711040.USD","LU0053666078.USD","LU0289739699.SGD","IE0002270589.USD","LU1430594728.SGD","LU1868836914.USD","BK4097","LU1670710661.SGD","LU1093756325.SGD","BK4578"],"gpt_icon":0},{"id":"2529150898","title":"Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2529150898","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529150898?lang=en_us&edition=fundamental","pubTime":"2025-04-23 18:15","pubTimestamp":1745403300,"startTime":"0","endTime":"0","summary":"Ivonescimab in Combination with Chemotherapy in the HARMONi-6 Study Conducted by Akeso Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC. PFS Improvement Was Observed across Tumors with PD-L1 Negative and PD-L1 Positive Expression in the HARMONi-6 Clinical Trial Conducted by Akeso. Full Data Set to be Presented at an Upcoming Major Medical Conference Planned for Later This Year. At a prespecified interim analysis conducted by an Independent Data Monitoring Committee, ivonescimab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS by blinded independent central radiology review committee  compared to tislelizumab plus chemotherapy. The PFS benefit was demonstrated in patients with either PD-L1-positive or PD-L1-negative tumors. Akeso noted that no new safety signals were identified in this Phase III study. The full data s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ivonescimab-combination-chemotherapy-achieves-statistically-101500586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SMMT","01698","BK4195","IE00BYTNYN87.SGD","BK4552","LU0359202008.SGD","PFS","LU0053666078.USD","BK4565","BK4211","LU1169589451.USD","IE00B12V2V27.USD","LU1169590202.USD","LU2488822045.USD","BK4588","TME","BK4531","L","IE00BYQNZ168.SGD","PD","LU1023057109.AUD","BK4571","SG9999011746.SGD","BK4107","LU0359201612.USD","BK4509","BK4585","BK4526","BK4139","BK4535","BK4108","BK4023","BK4548","LU2039709279.SGD","BK4563"],"gpt_icon":0},{"id":"2529154530","title":"3 Top Dividend Stocks Offering Up To 6.1% Yield","url":"https://stock-news.laohu8.com/highlight/detail?id=2529154530","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529154530?lang=en_us&edition=fundamental","pubTime":"2025-04-23 01:31","pubTimestamp":1745343103,"startTime":"0","endTime":"0","summary":"In a volatile market environment where the Dow Jones Industrial Average has recently surged over 1,000 points following steep declines, investors are keenly focused on finding stable income sources amidst uncertainty. Dividend stocks can offer a reliable stream of income and potential for capital appreciation, making them an attractive choice for those looking to navigate the current economic landscape with confidence.Click here to see the full list of 170 stocks from our Top US Dividend Stocks screener.Overview: Popular, Inc. operates through its subsidiaries to offer retail, mortgage, and commercial banking products and services in Puerto Rico, the United States, and the British Virgin Islands with a market cap of approximately $5.95 billion.Overview: National Bank Holdings Corporation is a bank holding company for NBH Bank, offering a range of banking products and financial services to commercial, business, and consumer clients in the United States, with a market cap of approximatel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-top-dividend-stocks-offering-173143223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CVX","LU1929549753.HKD","LU1116320737.USD","BK4570","US5Y.BOND","LU0256863811.USD","LU0612318971.USD","US3Y.BOND","BK4559","US10Y.BOND","DDS","LU1116320901.HKD","IPG","LU0266512127.USD","LU1162221912.USD","LU2129689514.USD","BK4566","BK4585","LU0265550359.USD","NBHC","LU2133065610.SGD","RF","LU1430597077.USD","LU0868494708.USD","LU0070302665.USD","BK4592","LU1201861165.SGD","LU0368265418.SGD","BK4195","LU0130103400.USD","LU1496350171.SGD","PFS","LU0320765646.SGD","BK4220","LU0300736062.USD","US30Y.BOND","US7Y.BOND","US2Y.BOND","LU0208291251.USD","LU0417517546.SGD","US6M.BOND","LU0300736492.USD","LU2129689431.USD","LU1066051498.USD","BPOP","LU0630314457.HKD","LU0345781412.USD","US12M.BOND","IE000M9KFDE8.USD","IE00B3CCJ963.GBP","LU0640476718.USD"],"gpt_icon":0},{"id":"2529737103","title":"Solaris completes Warintza drilling campaign and advances key de-risking milestones ahead of major near-term value catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2529737103","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529737103?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:00","pubTimestamp":1745319600,"startTime":"0","endTime":"0","summary":"Solaris completes significant drilling campaign at its flagship Warintza project. Updated Mineral Resource Estimate targeted for Q3 2025. Technical approval of the Environmental Impact Assessment on target for mid-2025. Re-election of President Daniel Noboa provides political stability, reinforcing the supportive policy environment. Between January 2024 and February 2025, Solaris completed over 82,000 metres of infill drilling, positioning the Company to upgrade a substantial portion of Inferred Resources to the Measured and Indicated categories. An updated Mineral Resource Estimate , targeted for Q3 2025, will incorporate this data, adding precision and confidence ahead of economic studies and advancing the Warintza Project toward development. The drilling campaign also included more than 15,000 metres of geotechnical, hydrogeological and metallurgical holes that will support the technical studies for the project.To date, Solaris has drilled over 200,000 metres across the Warintza Cen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/solaris-completes-warintza-drilling-campaign-110000187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EIA","PFS","BK4195","SLSR","BK4168","FID","BK4211"],"gpt_icon":0},{"id":"2529372711","title":"Health Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529372711","media":"CNW Group","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529372711?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:00","pubTimestamp":1745319600,"startTime":"0","endTime":"0","summary":"Approval is based on the results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial. \"This approval marks the first combination treatment of KEYTRUDA and chemotherapy in Canada for patients with malignant pleural mesothelioma,\" says Dr. Quincy Chu, Medical Oncologist at the Cross Cancer Institute and Associate Professor at the University of Alberta. \"This combination provides a new therapeutic option for this patient group, which has limited options available and may help improve health outcomes.\". The Phase 3 component of the trial enrolled 440 patients, regardless of tumour PD-L1 expression. Patients with autoimmune disease that required systemic therapy within three years of treatment or a medical condition that required immunosuppression were ineligible. Patients were randomized (1:1) to one of the following treatment arms; all study medications were administered via intravenous infusion:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/health-canada-approves-keytruda-plus-110000111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","IE00B1BXHZ80.USD","LU1430594728.SGD","BK4588","HR","LU1066051811.HKD","SG9999002224.SGD","SG9999013999.USD","IE0009355771.USD","PFS","IE00BBT3K403.USD","BK4148","LU1037948541.HKD","LU1066053197.SGD","LU1934455277.USD","LU0965509283.SGD","SG9999001176.SGD","IE00BJT1NW94.SGD","LU0203347892.USD","LU1093756325.SGD","LU1037948897.HKD","LU2089984988.USD","LU0234572021.USD","LU1571399168.USD","MRK","LU1585245621.USD","BK4211","LU0965508806.USD","IE00BSNM7G36.USD","LU0006306889.USD","CCTG","IE00B19Z4B17.USD","LU0965509101.SGD","LU0106261372.USD","LU0208291251.USD","OS","LU0265550946.USD","LU1057294990.SGD","BK4559","AEIS","IE000M9KFDE8.USD","BK4550","BK4157","LU2461242641.AUD","BK4203","ORR","LU0203345920.USD","LU1989772840.SGD","LU0266013472.USD","SGXZ57979304.SGD"],"gpt_icon":0},{"id":"2529139785","title":"Why DroneShield, Kingsgate, Santana, and Star shares are pushing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2529139785","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529139785?lang=en_us&edition=fundamental","pubTime":"2025-04-22 10:09","pubTimestamp":1745287788,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) has bounced back from a tough start and is trading flat. At the time of writing, the benchmark index is flat at 7,816.4 points. Four ASX shares that are rising more tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/22/why-droneshield-kingsgate-santana-and-star-shares-are-pushing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7095","BK4195","KCN.AU","BK7104","DRO.AU","XJO.AU","BK7078","SMI.AU","BK4211","BK7115","BK7062","RAS.AU","SGR.AU","PFS"],"gpt_icon":0},{"id":"2529907364","title":"Santana Minerals Refines Gold Project Strategy to Enhance Viability","url":"https://stock-news.laohu8.com/highlight/detail?id=2529907364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529907364?lang=en_us&edition=fundamental","pubTime":"2025-04-22 09:28","pubTimestamp":1745285325,"startTime":"0","endTime":"0","summary":"Santana Minerals Ltd. ( ($AU:SMI) ) has shared an update. Santana Minerals Ltd. has announced updates to its Pre-feasibility Study (PFS) for the Be...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/santana-minerals-refines-gold-project-strategy-to-enhance-viability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/santana-minerals-refines-gold-project-strategy-to-enhance-viability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4023","BK4195","BK4109","BK4596","STRK","PFS","BK4600","MTX","BK4516","BK4595","BK4585","BK4211"],"gpt_icon":0},{"id":"2529631283","title":"HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2529631283","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529631283?lang=en_us&edition=fundamental","pubTime":"2025-04-22 08:00","pubTimestamp":1745280000,"startTime":"0","endTime":"0","summary":"HONG KONG and FLORHAM PARK, N.J., April 22, 2025  -- HUTCHMED  Limited   today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib ingastric cancer patients with MET amplification.The China’s National Medical Products Administration  has granted Breakthrough Therapy Designation to savolitinib for the treatment of locally advanced or metastatic gastric cancer or GEJ adenocarcinoma patients with MET amplification who have failed at least two lines of standard therapies. If positive, HUTCHMED may initiate plans to apply for marketing authorization of savolitinib for gastric cancer in China in late 2025.MET-driven gastric cancer has a very poor prognosis.1 It is estimated that MET amplification accounts for approximately 4-6% of gastric cancer patients.2,3 The annual incidence of MET amplification gastric cancer is estimated to be approximately 18,000 in China.4 The ongoing registration trial follows multiple Phase II studies conducted ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hutchmed-completes-patient-enrollment-phase-000000433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4211","BK4195","HCM","TRAE","BK4531","BK4588","BK4007","PFS"],"gpt_icon":0},{"id":"2529689806","title":"Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529689806","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529689806?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:30","pubTimestamp":1745238600,"startTime":"0","endTime":"0","summary":"– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC –。– Trodelvy Plus Keytruda Shows an Early Trend in Improvement for Overall Survival Versus Standard of Care in Patients with Previously Untreated PD-L1+  mTNBC –。\"These findings are the first to show the transformative potential of an antibody-drug conjugate combined with an immuno-oncology agent in early treatment lines of metastatic breast cancer,\" said Dietmar Berger, MD, PhD, Chief Medical Officer, Gilead Sciences. \"For patients with this difficult to treat type of breast cancer, these results potentially offer a new pathway that may redefine their treatment options.\". The significant and meaningful improvement in PFS demonstrated in ASCENT-04 further reinforces the potential of Trodelvy plus Keytruda as a much-needed new treatment option for patients with previously untreated inoperable  PD-L1+ loca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/trodelvy-plus-keytruda-demonstrates-statistically-123000256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B1BXHZ80.USD","LU2106854487.HKD","BK4578","HR","SG9999002224.SGD","LU1035773651.USD","LU1066051225.USD","LU1069347547.HKD","SG9999001176.USD","LU0265550359.USD","PFS","PD","IE00BBT3K403.USD","IE00BKVL7J92.USD","LU0965509283.SGD","IE00BJT1NW94.SGD","SAR","ADC","LU0203347892.USD","SG9999002232.USD","LU1093756325.SGD","BK4007","LU2023250843.SGD","LU2112291526.USD","LU0234572021.USD","MCBS","CINV","MRK","LU1585245621.USD","SG9999014542.SGD","LU0965508806.USD","IE00BSNM7G36.USD","LU0861579265.USD","OS","LU0106261372.USD","LU0208291251.USD","LU1162221912.USD","LU2361045086.USD","LU0985320562.USD","IE000M9KFDE8.USD","LU2087621335.USD","BK4203","IE00BZ1G4Q59.USD","ORR","LU0203345920.USD","LU0109394709.USD","BK4585","LU1023059063.AUD","GILD","LU0234570918.USD"],"gpt_icon":0},{"id":"2529803706","title":"AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2529803706","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529803706?lang=en_us&edition=fundamental","pubTime":"2025-04-21 20:05","pubTimestamp":1745237101,"startTime":"0","endTime":"0","summary":"AstraZeneca Plc  on Monday released topline data from the DESTINY-Breast09 Phase 3 trial ofEnhertu either alone or in combination with pertuzumab versus standard of care THP  as a first-line treatment in patients with HER2-positive metastatic breast cancer.High-level results from a planned interim analysis showed Enhertu pertuzumab combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival  compared to THP.Also Read: European Drug Regulator Approves AstraZeneca’s Two Flagship Cancer Drugs For Breast And Lung Cancer Settings. HER2-positive metastatic breast cancer is an aggressive disease driven by overexpression or amplification of HER2, affecting 15-20% of patients with metastatic breast cancer.While HER2-targeted therapies have improved outcomes, prognosis remains poor, with most patients experiencing disease progression within two years of 1st-line treatment with THP, which has been the standard of care for more than a dec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-daiichi-sankyos-multi-billion-120501820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AZN","BK4195","LU0320765992.SGD","LU2456880835.USD","OS","LU2462157665.USD","PFS","LU0889565916.HKD","BK4211","BK4568","BK4097","BK4588","LU2236285917.USD","BK4007","ADC","DSKYF","BK4080","LU1829250122.USD","BK4585","BK4231","LU0109394709.USD","DSNKY","LU2417539215.USD"],"gpt_icon":0},{"id":"2529803700","title":"ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2+ metastatic breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2529803700","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529803700?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:00","pubTimestamp":1745233200,"startTime":"0","endTime":"0","summary":"DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care. WILMINGTON, Del., April 21, 2025----Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU  in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival  compared to a taxane, trastuzumab and pertuzumab  as a 1st-line treatment for patients with HER2-positive metastatic breast cancer.The PFS improvement was seen across all pre-specified patient subgroups with ENHERTU in combination with pertuzumab. The key secondary endpoint of overall survival  was not mature at the time of this planned interim analysis; however, interim OS data showed an early trend favoring the ENHERTU combination compared wit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-fam-trastuzumab-deruxtecan-nxki-110000627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0889565916.HKD","BK4568","LU2456880835.USD","BK4080","BK4588","BK4203","AZN","HR","LU2417539215.USD","LU0320765992.SGD","BK4097","BK4007","BK4195","ADC","BK4211","LU2462157665.USD","LU2236285917.USD","LU0109394709.USD","PFS","BK4231","BK4225","OS","LU1829250122.USD"],"gpt_icon":0},{"id":"2527241400","title":"Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527241400","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527241400?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:03","pubTimestamp":1744812204,"startTime":"0","endTime":"0","summary":"We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Relay Therapeutics Inc.  stands against other biotech penny stocks.Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas. First the vaccine approvals and the subsequent resurgence of new vaccines over the past two decades, and then the establishment of the cell and gene therapy field that he’s credited for. He was involved in developing policies aimed at optimizing the process of bringing several innovative products to the market. Following his resignation, a substantial number of other departures are also anticipated, which implies upcoming destabilization at the FDA for its existing expertise and processes.We sifted through ETFs, stock screeners, and financial media reports to compile a list of the top biotech penny stocks tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relay-therapeutics-inc-nasdaq-rlay-140324064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ",".IXIC","MNQmain","BK4139","USAW.SI","BK4211","LU2095319765.USD","BK4585","QLD","BK4588","BK4563","IE00B64PRP62.GBP","NVIW.SI","NDAQ","IE00B3QW5Z07.USD","LU2210149790.SGD","RLAY","TSYW.SI","IE00BKPKM429.USD","QID","NQmain","PFS","TQQQ","IE00BGHQF748.EUR","LU2210150020.SGD","USJW.SI","PSQ","BK4112","BK4195","ORR"],"gpt_icon":1},{"id":"2527427555","title":"Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2527427555","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527427555?lang=en_us&edition=fundamental","pubTime":"2025-04-16 04:05","pubTimestamp":1744747500,"startTime":"0","endTime":"0","summary":"- Initial results from randomized Phase 2 CRDF-004 trial in RAS-mut mCRC were released in December 2024 - - Additional clinical data from CRDF-004 trial expected in 1H 2025 - SAN DIEGO, April  15, 202","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/15/3062116/0/en/Cardiff-Oncology-Announces-Completion-of-Enrollment-in-Phase-2-CRDF-004-Trial-Evaluating-Onvansertib-for-the-Treatment-of-First-line-RAS-mutated-Metastatic-Colorectal-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0124384867.USD","LU1861220033.SGD","BK4211","LU1978683503.SGD","BK4139","LU1861215975.USD","BK4512","LU1854103824.USD","LU0724618433.USD","LU1854104046.USD","PFS","LU0348723411.USD","LU2298322129.HKD","BK4195","BK4141","IE00BZ199S13.USD","LU1720051108.HKD","LU2360107325.USD","ON","BK4605","LU2357305700.SGD","LU1861219969.SGD","LU1548497426.USD","ORR","CRDF","IE00BD6J9T35.USD","LU1861214812.USD","LU1720051017.SGD","BK4588"],"gpt_icon":0},{"id":"2527276154","title":"Here's Why Summit Therapeutics Stock Soared 15% on Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2527276154","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527276154?lang=en_us&edition=fundamental","pubTime":"2025-04-14 17:57","pubTimestamp":1744624620,"startTime":"0","endTime":"0","summary":"Shares of Summit Therapeutics SMMT rose more than 15% on Friday after the analysts at Cantor Fitzgerald and Truist Securities maintained their positive outlook on the company.Both investment firms remain optimistic about Summit Therapeutics’ lead pipeline drug, ivonescimab. This drug was developed in collaboration with China-based Akeso, which is also its original developer. Summit in-licensed the right to develop and market the drug in 2022 across several territories, including the United States and Europe.Cantor reportedly reiterated its Overweight rating on SMMT after an SEC filing revealed that the company’s co-chief executive officer , Bob Duggan, exercised warrants to acquire nearly 4 million shares of the company. This transaction was executed about four years before the warrants expired at a strike price of $1.58 each. The analyst pointed out that this indicated a bullish signal for the stock.Another regulatory filing also revealed that the company’s other co-CEO, Zanganeh Mahk","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-summit-therapeutics-stock-095700433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066051498.USD","BNTX","LU1571399168.USD","LU1934455194.USD","LU0203345920.USD","LU2361044949.HKD","OS","SMMF","LU0070302665.USD","LU0265550946.USD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU0965508806.USD","LU0965509101.SGD","LU1069347547.HKD","PFS","TIL","LU0320765646.SGD","LU1066051811.HKD","BK4568","MRK","LU0265550359.USD","LU1929549753.HKD","LU2106854487.HKD","SG9999014559.SGD","LU1093756168.USD","LU0289739699.SGD","IE00BN8TJ469.HKD","LU1116320737.USD","BK4195","LU1989772840.SGD","IE00BLSP4239.USD","LU0211331839.USD","SG9999015341.SGD","IE00BJJMRZ35.SGD","LU1941712348.USD","LU1162221912.USD","LU2488822045.USD","SMMT","BK4559","LU0266013472.USD","IE00BLSP4452.SGD","LU0203347892.USD","LU0965509283.SGD","LU1974910355.USD","LU2324357040.USD","LU1093756325.SGD","LU2468319806.SGD","LENZ","IE00B1BXHZ80.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFS\",params:#limit:5,,,undefined,":[{"date":"2025-05-16","symbol":"PFS","amount":0.24,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-16","defaultRemindTime":1747402200000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-16","currency":"USD","dateTimestamp":1747368000000,"payDate":"2025-05-30"},{"date":"2025-04-24","symbol":"PFS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.47,"defaultRemindTime":1745524800000,"name":null,"time":"Post Market","dateTimestamp":1745467200000,"actualEps":null},{"date":"2025-02-14","symbol":"PFS","amount":0.24,"announcedDate":"2025-01-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-14","defaultRemindTime":1739543400000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-28","payableDate":"2025-02-14","currency":"USD","dateTimestamp":1739509200000,"payDate":"2025-02-28"},{"market":"US","date":"2025-01-28","symbol":"PFS","fiscalQuarterEnding":"2024/12","expectedEps":0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738040400000,"reportTimeType":"post","actualEps":0.37},{"date":"2024-11-15","symbol":"PFS","amount":0.24,"announcedDate":"2024-10-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-15","defaultRemindTime":1731681000000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-29","payableDate":"2024-11-15","currency":"USD","dateTimestamp":1731646800000,"payDate":"2024-11-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFS\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-13","recordDate":"2015-05-15","paymentDate":"2015-05-29","value":0.16,"currency":"USD"},{"executeDate":"2015-08-12","recordDate":"2015-08-14","paymentDate":"2015-08-28","value":0.16,"currency":"USD"},{"executeDate":"2015-11-10","recordDate":"2015-11-13","paymentDate":"2015-11-27","value":0.17,"currency":"USD"},{"executeDate":"2016-02-10","recordDate":"2016-02-12","paymentDate":"2016-02-26","value":0.17,"currency":"USD"},{"executeDate":"2016-05-11","recordDate":"2016-05-13","paymentDate":"2016-05-31","value":0.18,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.8333,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1734321600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFS","date":"2025-04-28","current":14.654875,"percent":0.743902,"low":6.410614,"twenty":8.695921,"median":10.357421,"eighty":16.512412,"high":33.980228,"avg":12.887623,"sd":6.399504,"marketCap":2161169063},"quantilePoints":[{"date":"2020-05-01","current":9.095426,"twenty":14.024503,"median":17.544322,"eighty":19.049774,"marketCap":879291222},{"date":"2020-05-08","current":8.942283,"twenty":13.850794,"median":17.544322,"eighty":19.049774,"marketCap":864486279},{"date":"2020-05-15","current":7.690497,"twenty":13.45386,"median":17.544322,"eighty":19.049774,"marketCap":743471074},{"date":"2020-05-22","current":8.31639,"twenty":13.355525,"median":17.544322,"eighty":19.049774,"marketCap":803978677},{"date":"2020-05-29","current":8.675946,"twenty":13.325105,"median":17.544322,"eighty":19.049774,"marketCap":838738363},{"date":"2020-06-05","current":10.060901,"twenty":13.301991,"median":17.544322,"eighty":19.049774,"marketCap":972627526},{"date":"2020-06-12","current":8.802456,"twenty":13.236148,"median":17.54157,"eighty":19.049774,"marketCap":850968623},{"date":"2020-06-19","current":8.702579,"twenty":13.220184,"median":17.524378,"eighty":19.049774,"marketCap":841313155},{"date":"2020-06-26","current":8.695921,"twenty":13.193521,"median":17.503783,"eighty":19.049774,"marketCap":840669457},{"date":"2020-07-02","current":9.022184,"twenty":13.181803,"median":17.497343,"eighty":19.049774,"marketCap":872210654},{"date":"2020-07-10","current":8.9556,"twenty":13.133798,"median":17.475453,"eighty":19.049774,"marketCap":865773675},{"date":"2020-07-17","current":9.375082,"twenty":13.113766,"median":17.448564,"eighty":19.049774,"marketCap":906326643},{"date":"2020-07-24","current":9.601469,"twenty":13.098537,"median":17.431245,"eighty":19.049774,"marketCap":928212371},{"date":"2020-07-31","current":10.146984,"twenty":13.0648,"median":17.422118,"eighty":19.049774,"marketCap":878647633},{"date":"2020-08-07","current":10.689643,"twenty":13.048711,"median":17.403942,"eighty":19.049774,"marketCap":925637580},{"date":"2020-08-14","current":10.527035,"twenty":13.031177,"median":17.388517,"eighty":19.049774,"marketCap":911556975},{"date":"2020-08-21","current":9.599052,"twenty":13.008395,"median":17.362339,"eighty":19.049774,"marketCap":831201106},{"date":"2020-08-28","current":9.947973,"twenty":12.988694,"median":17.334295,"eighty":19.049774,"marketCap":861414913},{"date":"2020-09-04","current":10.155841,"twenty":12.944965,"median":17.31872,"eighty":19.049774,"marketCap":879414627},{"date":"2020-09-11","current":9.509966,"twenty":12.926046,"median":17.247931,"eighty":19.049774,"marketCap":823486942},{"date":"2020-09-18","current":9.539661,"twenty":12.903594,"median":17.204455,"eighty":19.049774,"marketCap":826058330},{"date":"2020-09-25","current":8.916057,"twenty":12.85637,"median":17.165483,"eighty":19.049774,"marketCap":772059186},{"date":"2020-10-02","current":9.457999,"twenty":12.836682,"median":17.1464,"eighty":19.049774,"marketCap":818987014},{"date":"2020-10-09","current":9.777225,"twenty":12.825762,"median":17.106994,"eighty":19.030829,"marketCap":846629433},{"date":"2020-10-16","current":9.658443,"twenty":12.807943,"median":17.057235,"eighty":18.996004,"marketCap":836343881},{"date":"2020-10-23","current":10.222656,"twenty":12.774984,"median":17.027417,"eighty":18.941136,"marketCap":885200250},{"date":"2020-10-30","current":10.595048,"twenty":12.75677,"median":16.971439,"eighty":18.91343,"marketCap":872343311},{"date":"2020-11-06","current":10.696549,"twenty":12.723452,"median":16.947615,"eighty":18.891695,"marketCap":880700321},{"date":"2020-11-13","current":13.674488,"twenty":12.723452,"median":16.898923,"eighty":18.890505,"marketCap":1125888942},{"date":"2020-11-20","current":14.639195,"twenty":12.723452,"median":16.877422,"eighty":18.890505,"marketCap":1205318094},{"date":"2020-11-27","current":15.191794,"twenty":12.723452,"median":16.856678,"eighty":18.890505,"marketCap":1250816345},{"date":"2020-12-04","current":16.053474,"twenty":12.723452,"median":16.820466,"eighty":18.876273,"marketCap":1321762772},{"date":"2020-12-11","current":16.072206,"twenty":12.723452,"median":16.79439,"eighty":18.876273,"marketCap":1323305085},{"date":"2020-12-18","current":16.222063,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1335643594},{"date":"2020-12-24","current":16.718466,"twenty":12.723452,"median":16.730308,"eighty":18.876273,"marketCap":1376514905},{"date":"2020-12-31","current":16.821493,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1384997630},{"date":"2021-01-08","current":18.095281,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1489874956},{"date":"2021-01-15","current":17.992254,"twenty":12.723452,"median":16.744122,"eighty":18.876273,"marketCap":1481392232},{"date":"2021-01-22","current":18.142111,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1493730740},{"date":"2021-01-29","current":14.720538,"twenty":12.723452,"median":16.78893,"eighty":18.876273,"marketCap":1427170886},{"date":"2021-02-05","current":15.094115,"twenty":12.723452,"median":16.757917,"eighty":18.876273,"marketCap":1463389586},{"date":"2021-02-12","current":15.571023,"twenty":12.723452,"median":16.755695,"eighty":18.876273,"marketCap":1509626224},{"date":"2021-02-19","current":15.626662,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1515020498},{"date":"2021-02-26","current":16.079724,"twenty":12.723452,"median":16.714233,"eighty":18.876273,"marketCap":1558945304},{"date":"2021-03-05","current":17.794179,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1725163471},{"date":"2021-03-12","current":18.789768,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1821686827},{"date":"2021-03-19","current":18.215526,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1766013442},{"date":"2021-03-26","current":18.002063,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1745317972},{"date":"2021-04-01","current":17.749069,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1720790008},{"date":"2021-04-09","current":18.24715,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1769079438},{"date":"2021-04-16","current":18.405271,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1784409415},{"date":"2021-04-23","current":18.674076,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1810470378},{"date":"2021-04-30","current":14.042944,"twenty":12.721872,"median":16.669814,"eighty":18.884491,"marketCap":1833713567},{"date":"2021-05-07","current":15.049841,"twenty":12.721872,"median":16.625436,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-05-14","current":15.169001,"twenty":12.721872,"median":16.591954,"eighty":18.884491,"marketCap":1980752967},{"date":"2021-05-21","current":15.133253,"twenty":12.721872,"median":16.545238,"eighty":18.884491,"marketCap":1976085049},{"date":"2021-05-28","current":15.049841,"twenty":12.721872,"median":16.529666,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-06-04","current":15.043883,"twenty":12.721872,"median":16.506308,"eighty":18.884491,"marketCap":1964415256},{"date":"2021-06-11","current":14.722153,"twenty":12.721872,"median":16.44402,"eighty":18.884491,"marketCap":1922403999},{"date":"2021-06-18","current":13.679507,"twenty":12.721872,"median":16.40509,"eighty":18.884491,"marketCap":1786256407},{"date":"2021-06-25","current":14.227641,"twenty":12.721872,"median":16.3245,"eighty":18.884491,"marketCap":1857831141},{"date":"2021-07-02","current":13.500768,"twenty":12.721872,"median":16.302281,"eighty":18.884491,"marketCap":1762916819},{"date":"2021-07-09","current":13.244575,"twenty":12.721872,"median":16.261288,"eighty":18.884491,"marketCap":1729463411},{"date":"2021-07-16","current":12.976467,"twenty":12.721872,"median":16.250162,"eighty":18.884491,"marketCap":1694454030},{"date":"2021-07-23","current":12.55345,"twenty":12.69964,"median":16.222063,"eighty":18.884491,"marketCap":1639217007},{"date":"2021-07-30","current":10.433885,"twenty":12.684833,"median":16.184117,"eighty":18.884491,"marketCap":1680450278},{"date":"2021-08-06","current":10.849309,"twenty":12.675728,"median":16.148152,"eighty":18.884491,"marketCap":1747357095},{"date":"2021-08-13","current":10.552042,"twenty":12.660863,"median":16.109223,"eighty":18.884491,"marketCap":1699480276},{"date":"2021-08-20","current":10.381313,"twenty":12.614911,"median":16.079724,"eighty":18.884491,"marketCap":1671983067},{"date":"2021-08-27","current":10.571012,"twenty":12.560516,"median":16.051403,"eighty":18.884491,"marketCap":1702535521},{"date":"2021-09-03","current":10.362343,"twenty":12.528973,"median":16.012247,"eighty":18.884491,"marketCap":1668927821},{"date":"2021-09-10","current":10.43348,"twenty":12.478039,"median":15.976834,"eighty":18.884491,"marketCap":1680384992},{"date":"2021-09-17","current":10.542557,"twenty":12.463634,"median":15.915973,"eighty":18.884491,"marketCap":1697952653},{"date":"2021-09-24","current":10.841334,"twenty":12.367008,"median":15.852207,"eighty":18.884491,"marketCap":1746072768},{"date":"2021-10-01","current":11.315583,"twenty":12.317066,"median":15.827979,"eighty":18.884491,"marketCap":1822453904},{"date":"2021-10-08","current":11.718695,"twenty":12.271397,"median":15.788905,"eighty":18.884491,"marketCap":1887377870},{"date":"2021-10-15","current":11.713953,"twenty":12.250326,"median":15.716295,"eighty":18.884491,"marketCap":1886614059},{"date":"2021-10-22","current":11.808802,"twenty":12.188782,"median":15.680935,"eighty":18.884491,"marketCap":1901890286},{"date":"2021-10-29","current":11.169949,"twenty":12.144658,"median":15.649322,"eighty":18.884491,"marketCap":1912127768},{"date":"2021-11-05","current":11.584988,"twenty":12.022084,"median":15.636232,"eighty":18.884491,"marketCap":1983176134},{"date":"2021-11-12","current":11.413559,"twenty":11.87183,"median":15.555472,"eighty":18.877325,"marketCap":1953830070},{"date":"2021-11-19","current":11.06619,"twenty":11.803248,"median":15.475641,"eighty":18.822017,"marketCap":1894365677},{"date":"2021-11-26","current":10.935362,"twenty":11.752841,"median":15.361209,"eighty":18.799671,"marketCap":1871969996},{"date":"2021-12-03","current":10.660174,"twenty":11.700674,"median":15.25837,"eighty":18.766081,"marketCap":1824861840},{"date":"2021-12-10","current":10.64664,"twenty":11.597269,"median":15.189807,"eighty":18.713257,"marketCap":1822545046},{"date":"2021-12-17","current":10.745888,"twenty":11.515514,"median":15.166494,"eighty":18.654746,"marketCap":1839534872},{"date":"2021-12-23","current":10.957919,"twenty":11.442431,"median":15.126556,"eighty":18.639247,"marketCap":1875831320},{"date":"2021-12-31","current":10.92634,"twenty":11.368446,"median":15.085589,"eighty":18.621596,"marketCap":1870425466},{"date":"2022-01-07","current":11.738372,"twenty":11.326022,"median":15.058778,"eighty":18.579091,"marketCap":2009433139},{"date":"2022-01-14","current":11.729349,"twenty":11.326022,"median":15.040904,"eighty":18.531427,"marketCap":2007888610},{"date":"2022-01-21","current":10.863182,"twenty":11.299875,"median":15.028989,"eighty":18.489553,"marketCap":1859613758},{"date":"2022-01-28","current":11.023748,"twenty":11.261979,"median":15.001772,"eighty":18.453467,"marketCap":1851118845},{"date":"2022-02-04","current":11.088134,"twenty":11.181448,"median":14.930112,"eighty":18.423167,"marketCap":1861930553},{"date":"2022-02-11","current":10.92717,"twenty":11.115728,"median":14.912327,"eighty":18.41438,"marketCap":1834901283},{"date":"2022-02-18","current":10.92717,"twenty":11.065654,"median":14.87528,"eighty":18.386528,"marketCap":1834901283},{"date":"2022-02-25","current":10.732094,"twenty":11.023748,"median":14.820597,"eighty":18.371521,"marketCap":1802143926},{"date":"2022-03-04","current":10.629654,"twenty":11.007105,"median":14.772796,"eighty":18.349914,"marketCap":1784942161},{"date":"2022-03-11","current":10.652348,"twenty":10.957288,"median":14.734826,"eighty":18.315942,"marketCap":1788752883},{"date":"2022-03-18","current":10.806664,"twenty":10.92634,"median":14.709739,"eighty":18.308123,"marketCap":1814665792},{"date":"2022-03-25","current":10.720428,"twenty":10.866543,"median":14.669048,"eighty":18.291682,"marketCap":1800185049},{"date":"2022-04-01","current":10.629654,"twenty":10.847714,"median":14.635382,"eighty":18.253335,"marketCap":1784942161},{"date":"2022-04-08","current":10.053238,"twenty":10.819838,"median":14.583758,"eighty":18.229989,"marketCap":1688149823},{"date":"2022-04-14","current":10.071393,"twenty":10.805336,"median":14.512906,"eighty":18.210171,"marketCap":1691198401},{"date":"2022-04-22","current":10.171245,"twenty":10.764,"median":14.497563,"eighty":18.192392,"marketCap":1707965577},{"date":"2022-04-29","current":10.150722,"twenty":10.733654,"median":14.451873,"eighty":18.177577,"marketCap":1657856535},{"date":"2022-05-06","current":10.297502,"twenty":10.713769,"median":14.383195,"eighty":18.14275,"marketCap":1681829155},{"date":"2022-05-13","current":9.954658,"twenty":10.67461,"median":14.304676,"eighty":18.117189,"marketCap":1625834598},{"date":"2022-05-20","current":10.078233,"twenty":10.650249,"median":14.249341,"eighty":18.096905,"marketCap":1646017372},{"date":"2022-05-27","current":10.572534,"twenty":10.629654,"median":14.193648,"eighty":18.064002,"marketCap":1726748469},{"date":"2022-06-03","current":10.412344,"twenty":10.620376,"median":14.117725,"eighty":18.057139,"marketCap":1700585614},{"date":"2022-06-10","current":10.000427,"twenty":10.605236,"median":13.994542,"eighty":18.016495,"marketCap":1633309699},{"date":"2022-06-17","current":9.92262,"twenty":10.570637,"median":13.872371,"eighty":17.998745,"marketCap":1620602026},{"date":"2022-06-24","current":10.165194,"twenty":10.552314,"median":13.685465,"eighty":17.991294,"marketCap":1660220065},{"date":"2022-07-01","current":10.513034,"twenty":10.530137,"median":13.611721,"eighty":17.968495,"marketCap":1717030837},{"date":"2022-07-08","current":10.31623,"twenty":10.524934,"median":13.456373,"eighty":17.95339,"marketCap":1684887900},{"date":"2022-07-15","current":10.288769,"twenty":10.512341,"median":13.392091,"eighty":17.910649,"marketCap":1680402839},{"date":"2022-07-22","current":10.613725,"twenty":10.505887,"median":13.327225,"eighty":17.849237,"marketCap":1733476061},{"date":"2022-07-29","current":11.467199,"twenty":10.505887,"median":13.302306,"eighty":17.813962,"marketCap":1809111112},{"date":"2022-08-05","current":11.377758,"twenty":10.505887,"median":13.239282,"eighty":17.786291,"marketCap":1795000639},{"date":"2022-08-12","current":11.739288,"twenty":10.505887,"median":13.221695,"eighty":17.762714,"marketCap":1852037025},{"date":"2022-08-19","current":11.748717,"twenty":10.505887,"median":13.209959,"eighty":17.748875,"marketCap":1853524605},{"date":"2022-08-26","current":11.296118,"twenty":10.505887,"median":13.188531,"eighty":17.733901,"marketCap":1782120768},{"date":"2022-09-02","current":10.848234,"twenty":10.505887,"median":13.150076,"eighty":17.684237,"marketCap":1711460720},{"date":"2022-09-09","current":10.928381,"twenty":10.505887,"median":13.130958,"eighty":17.66138,"marketCap":1724105150},{"date":"2022-09-16","current":11.036817,"twenty":10.505887,"median":13.113536,"eighty":17.644475,"marketCap":1741212319},{"date":"2022-09-23","current":10.980242,"twenty":10.505887,"median":13.081395,"eighty":17.623016,"marketCap":1732286840},{"date":"2022-09-30","current":9.193418,"twenty":10.478391,"median":13.065324,"eighty":17.59628,"marketCap":1450390441},{"date":"2022-10-07","current":9.075554,"twenty":10.469523,"median":13.052449,"eighty":17.561143,"marketCap":1431795692},{"date":"2022-10-14","current":9.580013,"twenty":10.437974,"median":13.034632,"eighty":17.546569,"marketCap":1511381219},{"date":"2022-10-21","current":9.716736,"twenty":10.425892,"median":13.011756,"eighty":17.514492,"marketCap":1532951128},{"date":"2022-10-28","current":10.271339,"twenty":10.389888,"median":12.992653,"eighty":17.479985,"marketCap":1683636796},{"date":"2022-11-04","current":10.266754,"twenty":10.377223,"median":12.955005,"eighty":17.444428,"marketCap":1682885173},{"date":"2022-11-11","current":10.291061,"twenty":10.357421,"median":12.934931,"eighty":17.408903,"marketCap":1686869566},{"date":"2022-11-18","current":10.064186,"twenty":10.320716,"median":12.924436,"eighty":17.359105,"marketCap":1649681083},{"date":"2022-11-25","current":10.272911,"twenty":10.310098,"median":12.883192,"eighty":17.323674,"marketCap":1683894487},{"date":"2022-12-02","current":10.204848,"twenty":10.293993,"median":12.857307,"eighty":17.216387,"marketCap":1672737942},{"date":"2022-12-09","current":9.973436,"twenty":10.282719,"median":12.842174,"eighty":17.162345,"marketCap":1634805690},{"date":"2022-12-16","current":9.360873,"twenty":10.269156,"median":12.829982,"eighty":17.036971,"marketCap":1534396787},{"date":"2022-12-23","current":9.719335,"twenty":10.253097,"median":12.811402,"eighty":16.964208,"marketCap":1593154590},{"date":"2022-12-30","current":9.69211,"twenty":10.230259,"median":12.79325,"eighty":16.866633,"marketCap":1588691972},{"date":"2023-01-06","current":9.896298,"twenty":10.216454,"median":12.770698,"eighty":16.761899,"marketCap":1622161606},{"date":"2023-01-13","current":10.150398,"twenty":10.193425,"median":12.743914,"eighty":16.690368,"marketCap":1663812707},{"date":"2023-01-20","current":10.213923,"twenty":10.187062,"median":12.725033,"eighty":16.523587,"marketCap":1674225482},{"date":"2023-01-27","current":9.790009,"twenty":10.173843,"median":12.690346,"eighty":16.324736,"marketCap":1719595430},{"date":"2023-02-03","current":10.396723,"twenty":10.16752,"median":12.677807,"eighty":16.256402,"marketCap":1826163591},{"date":"2023-02-10","current":10.238158,"twenty":10.16752,"median":12.667312,"eighty":16.23143,"marketCap":1798311961},{"date":"2023-02-17","current":10.259586,"twenty":10.15802,"median":12.637027,"eighty":16.127135,"marketCap":1802075695},{"date":"2023-02-24","current":10.011024,"twenty":10.149032,"median":12.580612,"eighty":16.062409,"marketCap":1758416384},{"date":"2023-03-03","current":9.946656,"twenty":10.12732,"median":12.54984,"eighty":16.029311,"marketCap":1747110222},{"date":"2023-03-10","current":8.806492,"twenty":10.110262,"median":12.491259,"eighty":15.99002,"marketCap":1546842669},{"date":"2023-03-17","current":8.551231,"twenty":10.087476,"median":12.467781,"eighty":15.924154,"marketCap":1502006690},{"date":"2023-03-24","current":8.308734,"twenty":10.075497,"median":12.378703,"eighty":15.861307,"marketCap":1459412470},{"date":"2023-03-31","current":8.159832,"twenty":10.060803,"median":12.352386,"eighty":15.839714,"marketCap":1433258125},{"date":"2023-04-06","current":7.704617,"twenty":10.04356,"median":12.287536,"eighty":15.796939,"marketCap":1353300555},{"date":"2023-04-14","current":7.832247,"twenty":10.027135,"median":12.261119,"eighty":15.730693,"marketCap":1375718565},{"date":"2023-04-21","current":7.74716,"twenty":10.017452,"median":12.211348,"eighty":15.694,"marketCap":1360773225},{"date":"2023-04-28","current":7.593207,"twenty":9.999766,"median":12.160062,"eighty":15.664957,"marketCap":1307717267},{"date":"2023-05-05","current":6.573548,"twenty":9.989771,"median":12.09154,"eighty":15.642667,"marketCap":1132109520},{"date":"2023-05-12","current":6.495446,"twenty":9.971621,"median":11.987273,"eighty":15.600987,"marketCap":1118658713},{"date":"2023-05-19","current":7.029498,"twenty":9.961387,"median":11.888242,"eighty":15.530275,"marketCap":1210634281},{"date":"2023-05-26","current":7.046909,"twenty":9.952827,"median":11.808802,"eighty":15.39865,"marketCap":1213632756},{"date":"2023-06-02","current":7.116551,"twenty":9.943684,"median":11.780347,"eighty":15.324881,"marketCap":1225626656},{"date":"2023-06-09","current":7.90873,"twenty":9.929925,"median":11.738372,"eighty":15.203096,"marketCap":1362057268},{"date":"2023-06-16","current":7.934846,"twenty":9.905841,"median":11.713953,"eighty":15.174007,"marketCap":1366554981},{"date":"2023-06-23","current":7.221014,"twenty":9.886325,"median":11.649929,"eighty":15.134319,"marketCap":1243617506},{"date":"2023-06-30","current":7.260188,"twenty":9.866996,"median":11.584988,"eighty":15.109317,"marketCap":1250364075},{"date":"2023-07-07","current":6.946798,"twenty":9.848756,"median":11.548897,"eighty":15.068412,"marketCap":1196391525},{"date":"2023-07-14","current":7.499583,"twenty":9.820363,"median":11.505283,"eighty":15.049841,"marketCap":1291593106},{"date":"2023-07-21","current":8.108951,"twenty":9.78572,"median":11.467199,"eighty":15.032889,"marketCap":1396539731},{"date":"2023-07-28","current":8.682159,"twenty":9.742349,"median":11.428126,"eighty":15.003286,"marketCap":1432521431},{"date":"2023-08-04","current":8.409258,"twenty":9.731294,"median":11.387173,"eighty":14.9415,"marketCap":1387493907},{"date":"2023-08-11","current":8.120111,"twenty":9.718285,"median":11.354912,"eighty":14.916422,"marketCap":1339785831},{"date":"2023-08-18","current":7.624539,"twenty":9.704927,"median":11.300777,"eighty":14.879018,"marketCap":1258018387},{"date":"2023-08-25","current":7.506329,"twenty":9.663774,"median":11.282731,"eighty":14.826043,"marketCap":1238514226},{"date":"2023-09-01","current":7.492689,"twenty":9.624389,"median":11.244446,"eighty":14.781733,"marketCap":1236263745},{"date":"2023-09-08","current":7.310828,"twenty":9.599052,"median":11.197237,"eighty":14.751943,"marketCap":1206257344},{"date":"2023-09-15","current":7.388119,"twenty":9.572255,"median":11.168825,"eighty":14.716388,"marketCap":1219010065},{"date":"2023-09-22","current":6.997117,"twenty":9.538302,"median":11.11225,"eighty":14.678775,"marketCap":1154496301},{"date":"2023-09-29","current":6.951652,"twenty":9.501581,"median":11.06619,"eighty":14.644899,"marketCap":1146994701},{"date":"2023-10-06","current":6.951652,"twenty":9.471361,"median":11.046743,"eighty":14.595078,"marketCap":1146994701},{"date":"2023-10-13","current":6.792523,"twenty":9.431033,"median":11.012054,"eighty":14.515019,"marketCap":1120739099},{"date":"2023-10-20","current":6.542463,"twenty":9.372419,"median":10.980475,"eighty":14.499896,"marketCap":1079480297},{"date":"2023-10-27","current":7.170747,"twenty":9.358917,"median":10.957919,"eighty":14.471655,"marketCap":1076479657},{"date":"2023-11-03","current":7.537213,"twenty":9.227549,"median":10.936586,"eighty":14.399708,"marketCap":1131493992},{"date":"2023-11-10","current":7.179977,"twenty":9.151165,"median":10.92634,"eighty":14.31961,"marketCap":1077865333},{"date":"2023-11-17","current":7.734589,"twenty":9.108811,"median":10.883634,"eighty":14.267749,"marketCap":1161124242},{"date":"2023-11-24","current":7.594687,"twenty":9.078197,"median":10.857,"eighty":14.214839,"marketCap":1140121995},{"date":"2023-12-01","current":7.60468,"twenty":8.976162,"median":10.840069,"eighty":14.143037,"marketCap":1141622155},{"date":"2023-12-08","current":8.214253,"twenty":8.928966,"median":10.82028,"eighty":14.03685,"marketCap":1233131947},{"date":"2023-12-15","current":9.103631,"twenty":8.896863,"median":10.805953,"eighty":13.930523,"marketCap":1366646233},{"date":"2023-12-22","current":9.083645,"twenty":8.896863,"median":10.78687,"eighty":13.759594,"marketCap":1363645912},{"date":"2023-12-29","current":9.223547,"twenty":8.892939,"median":10.761277,"eighty":13.668342,"marketCap":1384648159},{"date":"2024-01-05","current":8.743883,"twenty":8.862382,"median":10.745888,"eighty":13.56351,"marketCap":1312640455},{"date":"2024-01-12","current":8.583995,"twenty":8.806492,"median":10.720428,"eighty":13.408162,"marketCap":1288637886},{"date":"2024-01-19","current":8.309187,"twenty":8.772881,"median":10.697142,"eighty":13.342249,"marketCap":1247383472},{"date":"2024-01-26","current":8.828824,"twenty":8.752732,"median":10.656886,"eighty":13.316627,"marketCap":1325391819},{"date":"2024-02-02","current":9.490046,"twenty":8.752732,"median":10.64215,"eighty":13.30073,"marketCap":1218502920},{"date":"2024-02-09","current":8.830529,"twenty":8.752732,"median":10.629654,"eighty":13.236743,"marketCap":1133822213},{"date":"2024-02-16","current":9.326626,"twenty":8.752732,"median":10.620577,"eighty":13.221244,"marketCap":1197520090},{"date":"2024-02-23","current":8.865547,"twenty":8.752732,"median":10.61055,"eighty":13.209959,"marketCap":1138318534},{"date":"2024-03-01","current":8.801346,"twenty":8.74965,"median":10.589265,"eighty":13.19135,"marketCap":1130075279},{"date":"2024-03-08","current":8.986315,"twenty":8.743883,"median":10.567288,"eighty":13.154274,"marketCap":1153824926},{"date":"2024-03-15","current":8.329352,"twenty":8.723902,"median":10.538449,"eighty":13.128485,"marketCap":1069472190},{"date":"2024-03-22","current":8.96157,"twenty":8.698898,"median":10.5269,"eighty":13.112465,"marketCap":1150647615},{"date":"2024-03-28","current":8.466976,"twenty":8.693607,"median":10.517516,"eighty":13.098537,"marketCap":1087142753},{"date":"2024-04-05","current":8.466976,"twenty":8.653336,"median":10.488954,"eighty":13.065324,"marketCap":1087142753},{"date":"2024-04-12","current":7.990046,"twenty":8.61897,"median":10.476162,"eighty":13.052449,"marketCap":1025905922},{"date":"2024-04-19","current":8.671317,"twenty":8.578848,"median":10.466677,"eighty":13.034632,"marketCap":1040072426},{"date":"2024-04-26","current":9.585747,"twenty":8.579877,"median":10.437517,"eighty":13.020302,"marketCap":1149752791},{"date":"2024-05-03","current":9.605463,"twenty":8.579877,"median":10.431596,"eighty":12.999364,"marketCap":1152117669},{"date":"2024-05-10","current":10.091416,"twenty":8.579877,"median":10.40199,"eighty":12.962642,"marketCap":1210404831},{"date":"2024-05-17","current":10.167149,"twenty":8.579877,"median":10.387579,"eighty":12.944965,"marketCap":1219488545},{"date":"2024-05-24","current":9.554974,"twenty":8.579877,"median":10.368229,"eighty":12.926046,"marketCap":1146061860},{"date":"2024-05-31","current":9.031155,"twenty":8.579877,"median":10.357421,"eighty":12.90972,"marketCap":1083232842},{"date":"2024-06-07","current":8.639868,"twenty":8.579877,"median":10.32448,"eighty":12.882781,"marketCap":1036300321},{"date":"2024-06-14","current":8.494713,"twenty":8.57296,"median":10.31623,"eighty":12.877209,"marketCap":1018889870},{"date":"2024-06-21","current":8.53258,"twenty":8.56142,"median":10.296725,"eighty":12.877995,"marketCap":1023431727},{"date":"2024-06-28","current":8.608313,"twenty":8.557426,"median":10.288769,"eighty":12.87427,"marketCap":1032515441},{"date":"2024-07-05","current":9.17631,"twenty":8.557426,"median":10.28051,"eighty":12.856219,"marketCap":1100643293},{"date":"2024-07-12","current":10.066172,"twenty":8.557426,"median":10.267199,"eighty":12.83418,"marketCap":1207376927},{"date":"2024-07-15","current":10.141905,"twenty":8.557426,"median":10.266754,"eighty":12.829982,"marketCap":1216460640},{"date":"2024-08-02","current":30.236968,"twenty":8.550513,"median":10.244363,"eighty":12.813454,"marketCap":2311767376},{"date":"2024-08-09","current":28.994819,"twenty":8.550513,"median":10.244363,"eighty":12.829982,"marketCap":2216798880},{"date":"2024-08-16","current":30.839915,"twenty":8.550513,"median":10.244363,"eighty":12.847792,"marketCap":2357865738},{"date":"2024-08-23","current":30.942317,"twenty":8.550513,"median":10.244363,"eighty":12.868391,"marketCap":2365694844},{"date":"2024-08-30","current":32.290603,"twenty":8.550513,"median":10.244363,"eighty":12.926535,"marketCap":2468778073},{"date":"2024-09-06","current":31.86393,"twenty":8.550513,"median":10.244363,"eighty":12.95098,"marketCap":2436156798},{"date":"2024-09-13","current":30.379109,"twenty":8.550513,"median":10.244363,"eighty":12.978743,"marketCap":2322634762},{"date":"2024-09-20","current":33.178083,"twenty":8.550513,"median":10.244363,"eighty":12.986356,"marketCap":2536630324},{"date":"2024-09-27","current":30.92525,"twenty":8.550513,"median":10.244363,"eighty":13.030742,"marketCap":2364389993},{"date":"2024-10-04","current":30.174306,"twenty":8.550513,"median":10.244363,"eighty":13.065239,"marketCap":2306976550},{"date":"2024-10-11","current":30.874049,"twenty":8.550513,"median":10.244363,"eighty":13.110396,"marketCap":2360475440},{"date":"2024-10-18","current":33.980228,"twenty":8.550513,"median":10.244363,"eighty":13.135891,"marketCap":2597958321},{"date":"2024-10-25","current":32.512473,"twenty":8.550513,"median":10.244363,"eighty":13.18261,"marketCap":2485741135},{"date":"2024-10-31","current":26.328623,"twenty":8.550513,"median":10.244363,"eighty":13.18261,"marketCap":2483131433},{"date":"2024-11-08","current":29.275547,"twenty":8.550153,"median":10.241149,"eighty":13.17502,"marketCap":2761064694},{"date":"2024-11-15","current":29.635999,"twenty":8.550153,"median":10.241149,"eighty":13.220364,"marketCap":2795059964},{"date":"2024-11-22","current":28.847366,"twenty":8.550153,"median":10.241149,"eighty":13.27236,"marketCap":2720681617},{"date":"2024-11-29","current":29.220929,"twenty":8.550153,"median":10.241149,"eighty":13.402862,"marketCap":2755913466},{"date":"2024-12-06","current":28.529146,"twenty":8.550153,"median":10.241149,"eighty":13.662197,"marketCap":2690669302},{"date":"2024-12-13","current":28.10024,"twenty":8.550153,"median":10.241149,"eighty":13.941658,"marketCap":2650217921},{"date":"2024-12-20","current":25.789683,"twenty":8.550153,"median":10.241149,"eighty":14.183552,"marketCap":2432302415},{"date":"2024-12-27","current":26.509138,"twenty":8.550153,"median":10.241149,"eighty":14.332934,"marketCap":2500156345},{"date":"2025-01-03","current":25.734341,"twenty":8.550153,"median":10.241149,"eighty":14.482787,"marketCap":2427082882},{"date":"2025-01-10","current":25.720505,"twenty":8.549794,"median":10.239653,"eighty":14.532851,"marketCap":2425777998},{"date":"2025-01-17","current":26.619823,"twenty":8.549794,"median":10.239653,"eighty":14.674786,"marketCap":2510595411},{"date":"2025-01-24","current":26.24626,"twenty":8.549794,"median":10.239653,"eighty":14.756709,"marketCap":2475363563},{"date":"2025-01-31","current":20.963976,"twenty":8.549794,"median":10.239653,"eighty":14.865144,"marketCap":2421863349},{"date":"2025-02-07","current":22.127386,"twenty":8.549794,"median":10.239653,"eighty":14.930454,"marketCap":2556266325},{"date":"2025-02-14","current":21.3819,"twenty":8.549794,"median":10.239653,"eighty":15.030776,"marketCap":2470144030},{"date":"2025-02-21","current":20.6703,"twenty":8.549794,"median":10.239653,"eighty":15.049841,"marketCap":2387936384},{"date":"2025-02-28","current":20.24108,"twenty":8.549794,"median":10.239653,"eighty":15.119808,"marketCap":2338350819},{"date":"2025-03-07","current":19.574836,"twenty":8.549435,"median":10.238158,"eighty":15.219892,"marketCap":2261382913},{"date":"2025-03-14","current":18.818048,"twenty":8.556094,"median":10.256731,"eighty":15.427951,"marketCap":2173954953},{"date":"2025-03-21","current":19.168203,"twenty":8.563982,"median":10.270461,"eighty":15.642559,"marketCap":2214406696},{"date":"2025-03-28","current":19.642608,"twenty":8.589386,"median":10.284192,"eighty":15.976834,"marketCap":2269212283},{"date":"2025-04-04","current":18.08385,"twenty":8.61897,"median":10.295948,"eighty":16.156501,"marketCap":2089136782},{"date":"2025-04-11","current":16.76376,"twenty":8.629342,"median":10.308893,"eighty":16.250162,"marketCap":1936633430},{"date":"2025-04-17","current":17.215614,"twenty":8.672243,"median":10.320508,"eighty":16.320056,"marketCap":1988833792},{"date":"2025-04-25","current":14.956124,"twenty":8.693028,"median":10.339114,"eighty":16.512412,"marketCap":2205594545},{"date":"2025-04-28","current":14.654875,"twenty":8.695921,"median":10.357421,"eighty":16.512412,"marketCap":2161169063}],"updateTime":1745924321162}}}